Transmitted antiretroviral drug resistance has been an ongoing consideration even in patients who are treatment naive. The authors retrospectively selected all eligible patients from a US-based urban HIV clinic who had a genotypic resistance assay performed prior to the initiation of antiretroviral therapy. Clinically significant resistance was detected in 8% of assays, and was comparable when stratified by duration of time from diagnosis to genotypic resistance assay.
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Keywords: HIV; antiretroviral-naive; genotypic; resistance testing U pdated US HIV treatment guidelines now recommend routine genotypic resistance testing for all HIV-infected patients prior to initiation of antiretroviral therapy (ART), regardless of duration of infection and also comment that genotypic resistance testing may be considered in patients entering into care but not yet requiring therapy. 1 The prevalence of drug resistance in treatmentnaive patients in the United States is reported to range from 10% to 25% during 2003-2006, 2 with a higher prevalence in many metropolitan areas. After increasing for many years, the prevalence of HIV-1 drug resistance to any drug has remained stable at approximately 10.5% over the last 6 to 7 years. 3 It is only recently that the use of resistance testing has been associated with enhanced survival. 4 In addition, transmitted drug resistance has been shown to have a negative impact on response to initial ART in both acutely and chronically infected patients. 5, 6 Drug-resistance testing in antiretroviral-naive patients has been shown to be cost-effective when the prevalence of transmitted drug resistance is greater than 1%. 7 Although transmitted drug resistance has been well documented in several studies, most are of small sample size. Thus, we attempted to define the prevalence of drug resistance among antiretroviral-naive individuals with unknown duration of infection accessing medical care in a US-based urban HIV clinic.
Methods
A retrospective chart review of primarily indigent patients from a US-based urban HIV clinic in Wilmington, Delaware, was conducted from July 1, 2006, to July 1, 2008. Eligible patients included all antiretroviral-naive individuals, irrespective of duration of infection, who had a genotypic resistance assay performed prior to initiation of ART based on the revised US Department of Health and Human Services (DHHS) recommendation from May 2006. 1 This included all patients new to care or previously engaged in care, as long as they were naive to ART. Information collected included patient demographics, baseline CD4 count and HIV RNA measurements, duration of infection, and documented International AIDS Society-USA panel (IAS-USA)defined drug resistance-associated mutations. 8 In patients with multiple protease inhibitor mutations, the Stanford University HIV Drug Resistance Database 9 was used to ensure that these mutation pairs or combinations would not confer clinically significant resistance to one or more agents. In addition, a post hoc analysis was conducted to ascertain whether duration of infection resulted in differences in viral resistance. Because the duration of infection was unknown, patients were stratified according to HIV-testing dates; recently tested patients were tested after July 1, 2004, remotely tested patients were tested prior to July 1, 2004.
Results
A total of 100 patients met inclusion criteria. The majority of patients were male (63%) and African American (78%). The most prevalent transmission route reported was heterosexual (54%). Median duration of diagnosed HIV infection prior to genotypic resistance testing was 44 days (range 0-7687 days). Median baseline CD4 count and HIV RNA were 353 cells/mm 3 (range 10-1239 cells/mm 3 ) and 49 200 copies/mL (range 441-2 420 000 copies/mL) at the time of genotypic testing, respectively. A total of 167 resistance mutations were identified and 7 patients had no mutations detected. In the 93 patients with documented resistance, there was a median of 2 mutations per patient. Mutations were identified in reverse transcriptase (M41L, M184V, A98G, K103N, V108I, V179D, and Y188H) and protease (L10F/I/R/V, I13V, G16E, M36I/L/V, M46I, Q58E, D60E, I62V, L63P, H69K, A71V/T, V77I, and I93L) genes in 8% and 92% of assays, respectively. However, clinically significant resistance was only detected in 8% of patients ( Table 1) .
The majority of our cohort (n ¼ 80) was diagnosed with HIV infection on July 1, 2004, or later and were termed the recently tested group. Patients who tested HIV positive prior to July 1, 2004, were the remotely tested group. The largest difference between the two groups was the median length of time from HIV testing to genotypic assay, which was 36 days (range 0-1144 days) in the recently tested group compared to 1939 days (range 943-7687 days) in the remotely tested group. Although the majority of significant mutations were detected in the recently tested group (6/8), the resistance rates between the recently and remotely tested groups were comparable at 7.5% and 10%, respectively (P ¼ .66).
Discussion
Mutations consistent with the current IAS-USAdefined drug resistance-associated mutations were detected in the majority of patients. Protease inhibitor associated mutations far exceeded reverse transcriptase inhibitor mutations, although none conferred clinically significant resistance, even in combination, based on the Stanford University HIV Drug Resistance Database. 9 All reverse transcriptase inhibitor mutations detected, however, were considered clinically significant.
Regional and community differences may play a role in the variable prevalence seen in some studies. Studies that look at specific geographic cohorts have reported antiretroviral resistance rates which range from 10% to 25%. 2 One study conducted in San Diego, California, noted baseline resistance rate of 25%, 10 while another study conducted in New York City found baseline resistance in 24.1% 11 of patients. However, the prevalence of clinically significant mutations found in our clinic was not markedly different from the 12.1% reported in a recent study of antiretroviral-naive patients of 19 HIV clinics. 2 In addition, a study of 491 chronically HIV-infected, antiretroviral-naive patients in 25 cities found the prevalence of at least 1 resistance mutation to be 10.8%. This study also found that the prevalence of resistance was reduced to 8.8% if the reverse transcriptase mutation, V118I, was excluded. 12 The exclusion of the V118I mutation potentially explains the difference between our results and those found in other studies. The V118I mutation was removed from the list of IAS-USA-defined drug resistanceassociated mutations in 2006, 13 and was therefore not collected in our cohort.
A potential limitation to this study is that in many cases the baseline genotype was not drawn at the 
1 (1) Total 8 (8) time of the patient's diagnosis of HIV infection. Many of the patients in our study have an unknown duration of infection or were diagnosed prior to the updated DHHS recommendation that baseline genotypes should be considered in patients upon entry into care, even when treatment is not being initiated. Overall, the frequency of significant reverse transcriptase mutations was 8% in our cohort and although there was not a statistically significant difference in the prevalence of resistance between recently and remotely tested individuals, 75% of significant mutations were detected in the recently tested group. However, small sample size, particularly of the remotely tested group, potentially limits the ability to compare results based on duration of infection.
The data presented in this study support the recommendation for routine genotypic resistance testing for all HIV-infected patients prior to initiation of ART, regardless of duration of infection. 1 Detection of clinically significant resistance, specifically the detection of the K103N in 2 patients, emphasizes the need for resistance testing prior to selection of initial therapy. Resistance testing at baseline is considered cost-effective and may improve outcomes when the prevalence of resistance exceeds 1%, 7 a level far less than that found in our study. Resistance testing at baseline allows practitioners to be aware of the resistance trends in their own community and aid in selection of initial therapy. Notably, the relatively low level of resistance detected in our population may be reflective of long-standing HIV infection and regional variation. Monitoring future trends across geographic areas will continue to be important to optimize antiretroviral prescribing patterns.
